Distribution and Metabolism of the Potential Anti-Parkinson Drng Memantine in the Human

  • W. Wesemann
  • G. Sturm
  • E. W. Fünfgeld
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 16)


GC-MS of tissue extracts obtained from a parkinsonian patient who died from secondary causes during memantine (l-amino-3.5-dimethyl- adamantane) treatment showed the drug to be largely unmetabolized. In the kidney and liver a second peak corresponded to less than 1% of the main peak. In the brain an accumulation of memantine could be shown in the temporal lobe, hypothalamus and pons. Thus treatment with 2×10 mg memantine/day reveals an accumulation of the drug in µM concentrations in the brain. This is probably high enough to explain the ameliorating effect of memantine treatment in patients suffering from Parkinson’s disease.


Temporal Lobe Parkinsonian Patient Amantadine Hydrochloride Analyse Brain Region Isolate Nerve Ending 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bleidner, W. EHarmon, J. B., Hewes, W. E., Lynes, T. E., Hermann, E. C.: Absorption, distribution and excretion of amantadine hydrochloride. J. Pharmacol. Exp. Therap. 150, 484–490 (1965).Google Scholar
  2. Cupp, J., Klymkowski, M., Sands, J, Reith, A., Snipes, W.: Effect of lipid alkyl diain perturbations on the assembly of bacteriophage PM 2. Bio- chim. Biophys. Acta 389, 345–357 (1975).CrossRefGoogle Scholar
  3. Eletr, S., Williams, M. A., Watkins, T., Reith, A. D.: Perturbations of the dynamics of lipid alkyl chains in membrane systems: Effect on the activity of membrane-bound enzymes. Biochim. Biophys. Acta 339, 190–201 (1974).CrossRefGoogle Scholar
  4. Fischer, P.-A., Jacobi, P., Schneider, E., Schönberger, D.: Die Wirkung intravenöser Gaben von Memantin bei Parkinson-Kranken. Arzneim.-Forsch. (Drug Res.) 27, 1487–1489 (1977).Google Scholar
  5. Fünfgeld, E. W.: 33 Monate Therapie mit Dimethylaminoadamantan. Unpublished paper (1975).Google Scholar
  6. Fünfgeld, E. W.: Konservative Behandlung des Parkinsonismus. Vortrag und Film. Medizin. Gesellschaft Freiburg/Breisgau, February 3, 1976.Google Scholar
  7. Grossmann, W., Jurna, J.: Die Wirkung von Memantin auf die Membranen sensibler Nervenfaserbündel. Arzneim.-Forsch. (Drug Res.) 27, 1483 to 1487 (1977).Google Scholar
  8. Maj, J., Marchaj, J., Mogilnicka, E.: The effect of dimethyladamantane on the brain 5-hydroxytryptamine and 5-hydroxyindoleacetic acid levels. Second Congr. Hung. Pharmacol. Soc. Budapest, 1974.Google Scholar
  9. Maj, J., Dopaminergic drugs and Serotonin neurons. In: Current Developments in Psydhopharmacology (Essman, W. B., Valzelli, L., eds.), Vol. 3, pp. 55–83. NewYork-Toronto-London-Sydney: Spectrum. 1976.Google Scholar
  10. Svensson, T. H.: Dopamine release and direct dopamine receptor activation in the central nervous system by D 145, an amantadine derivative. Eur. J. Pharmacol. 23, 232–238 (1973).PubMedCrossRefGoogle Scholar
  11. Wesemann, W., Schollmeyer, J. D., Sturm, G.: Gaschromatographische und massenspektrometrische Untersuchungen über harnpflichtige Metaboliten von Adamantanaminen. Arzneim.-Forsch. (Drug Res.) 27, 1471–1476 (1977).Google Scholar
  12. Wesemann, W., Dette-Wildenhahn, G., Fellehner, H.: In vitro studies on the possible effects of 1-aminoadamantanes on the serotonergic system in M. Parkinson. J. Neural Transm. 44, 263–285 (1979).CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1980

Authors and Affiliations

  • W. Wesemann
    • 1
    • 4
  • G. Sturm
    • 2
  • E. W. Fünfgeld
    • 3
  1. 1.Abteilung für Neurochemie, Physiologisch-Chemisches Institut IIPhilipps-UniversitätMarburg/LahnFederal Republic of Germany
  2. 2.UniversitätsfrauenklinikPhilipps-UniversitätMarburg/LahnFederal Republic of Germany
  3. 3.Psychiatrisches KrankenhausMarburg/LahnFederal Republic of Germany
  4. 4.Abteilung für Neurochemie, Physiologisch-Chemisches Institut IIPhilippsUniversitätMarburg/LahnFederal Republic of Germany

Personalised recommendations